These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2892083)

  • 41. [Double-blind study of proglumide, zolimidine and carbenoxolone in peptic ulcer and gastroduodenitis].
    Corazza GR; D'Ambro A; Grimoldi D
    Minerva Dietol Gastroenterol; 1979; 25(1):47-58. PubMed ID: 156316
    [No Abstract]   [Full Text] [Related]  

  • 42. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.
    Coyle C; Crawford G; Wilkinson J; Thomas SJ; Bytzer P
    Aliment Pharmacol Ther; 2017 Jun; 45(12):1524-1533. PubMed ID: 28464343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Value of biogastrone and duodenal biogastrone in the treatment of peptic ulcer].
    Stadnicki A
    Pol Tyg Lek; 1979 Jun; 34(26):1029-31. PubMed ID: 503921
    [No Abstract]   [Full Text] [Related]  

  • 44. [Undesirable effects of Biogastrone in the treatment of peptic ulcer (author's transl)].
    Zelenková J; Toman R; Svoboda M; Svihovec J
    Cesk Gastroenterol Vyz; 1976 Oct; 30(7):427-33. PubMed ID: 797473
    [No Abstract]   [Full Text] [Related]  

  • 45. [Evaluation of the neutralizing activity on gastric acidity of a carbenoxolone-antacid formulation using computerized gastric pH-metry in healthy volunteers].
    Passaretti S; Tittobello A
    Clin Ter; 1988 Mar; 124(5):357-61. PubMed ID: 2974345
    [No Abstract]   [Full Text] [Related]  

  • 46. Long-term therapy with carbenoxolone in the prevention of recurrence of gastric ulcer. Natural history and evolution of important side-effects and measures to avoid them.
    Ganguli PC; Mohamed SD
    Scand J Gastroenterol Suppl; 1980; 65():63-71. PubMed ID: 6937941
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Carbenoxolone in the treatment of duodenal ulcer].
    Kadish U; Neeman A
    Harefuah; 1979 Sep; 97(5-6):111-2. PubMed ID: 540839
    [No Abstract]   [Full Text] [Related]  

  • 48. The biochemical pharmacology of carbenoxolone. Its possible mechanisms of action.
    Parke DV
    Acta Gastroenterol Belg; 1983; 46(9-10):437-47. PubMed ID: 6369855
    [No Abstract]   [Full Text] [Related]  

  • 49. [Controlled clinical study of the effectiveness of a new anti-ulcer drug: thiopropamine].
    Masoero G
    Clin Ter; 1979 Aug; 90(3):261-72. PubMed ID: 399873
    [No Abstract]   [Full Text] [Related]  

  • 50. [Tolerance of carbenoxolone sodium in elderly patients (author's transl)].
    Hagenmüller F; Wurbs D; Classen M
    Leber Magen Darm; 1977 Dec; 7(6):385-8. PubMed ID: 593029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Esophageal reflux and peptic ulcer. An exclusive advanced education service of the Gastro-Liga for family physicians].
    Fortschr Med; 1998 Dec; 116(34):35-8. PubMed ID: 10024760
    [No Abstract]   [Full Text] [Related]  

  • 52. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
    Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
    Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.
    Wilkinson J; Wade A; Thomas SJ; Jenner B; Hodgkinson V; Coyle C
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):86-93. PubMed ID: 30272584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Duodenal ulcer treated by carbenoxolone sodium. Endoscopically controlled trial (author's transl)].
    Carrilho FJ; Onishi I; Soares EC; Zeitune JM; Pareja JC; Amorim Filho J
    Arq Gastroenterol; 1978; 15(4):167-74. PubMed ID: 749854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Algicon in the management of gastro-oesophageal reflux.
    Lambert JR; Korman MG; Nicholson L
    Br J Clin Pract Suppl; 1989 Feb; 66():56-8; discussion 61-4. PubMed ID: 2556177
    [No Abstract]   [Full Text] [Related]  

  • 56. [Treatment of gastro-esophageal reflux using a potable gaviscon suspension].
    Guerre J; Neuman M; Bouchet J
    Med Chir Dig; 1982; 11(4):289-95. PubMed ID: 6287126
    [No Abstract]   [Full Text] [Related]  

  • 57. Importance of defensive factors in the prevention of peptic ulcer recurrence. Role of carbenoxolone sodium.
    Guslandi M
    Acta Gastroenterol Belg; 1983; 46(9-10):411-8. PubMed ID: 6673456
    [No Abstract]   [Full Text] [Related]  

  • 58. Carbenoxolone-induced hypokalaemia simulating Guillain-Barré syndrome.
    Royston A; Prout BJ
    Br Med J; 1976 Jul; 2(6028):150-1. PubMed ID: 1276838
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparative intragastric pH profile of Algicon versus Gaviscon.
    Stoddard CJ; Morgan GE
    Br J Clin Pract Suppl; 1989 Feb; 66():29-34; discussion 35-6. PubMed ID: 2556174
    [No Abstract]   [Full Text] [Related]  

  • 60. Cytoprotective therapy of gastric ulcers: a controlled clinical evaluation of triletide versus carbenoxolone.
    Campisi D; Cataldo MG; Paterna S; Bivona A; Barbarino C
    Pharmatherapeutica; 1985; 4(3 Spec No):166-70. PubMed ID: 3903785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.